Feasibility of the Use of Novel Hemostatic Sealant (Tisseel) in Laparoscopic Ovarian Cystectomy of Endometrioma

Objective: To evaluate the use of Tisseel, a two-component fibrin sealant agent, for the control of minor bleeding and repair of the ovarian defect at the end of laparoscopic cystectomy (LC) of endometriomas. Materials and Methods: From January 2014 to December 2014, an observational study of all patients who underwent LC of endometrioma using Tisseel was performed. The LC by the stripping technique is similar to that described earlier.1–3 The demographic and operative data, including age, body mass index, operative indications, operative time, estimated blood loss, complications, and postoperative hospital stay duration, were recorded. A matched cohort of patients, who underwent LC of endometrioma without Tisseel, was also retrospectively compared. Results: Thirteen women with symptomatic ovarian endometrioma were enrolled in the study (group A). A homogenous group of 26 patients (2 to 1 matched), with the same preoperative characteristics as the study group, were also selected as the control group (group B). Complete hemostasis was achieved in all patients. The median operating time (97 vs 106 minutes, respectively; p = 0.340), operative blood loss (50 vs 50 mL, respectively; p = 0.217), and length of hospitalization (2 vs 2 days, respectively; p = 0.582) were not significantly different between the two groups. No patients in either group had serious complications or required blood transfusion. Conclusions: This preliminary series demonstrated the use of Tisseel in LC of endometriomas without any bipolar coagulation and/or suturing of ovarian tissue is clinically safe and feasible. No competing financial interests exist. Runtime of video: 1 min 13 secs